RBM39 and cancer: Another aspect of our findings is the recognition that aryl sulfonamides may cause broad metabolic deficiencies and growth inhibition in cancer cells via the mechanism of RBM39 depletion and mis-splicing of specific genes which regulate metabolism and cell cycle.